top of page


where phages go clinical

Development and clinical trials of a modern drug
it treats bacterial infections


August 2022 - Application for clinical trials successfully submitted to the State Institute for Drug Control

January 2023 - Clinical trials approved by the State Institute for Drug Control



  • is an alternative to antibiotics;

  • is an innovative biological medicine containing bacteriophages;

  • enables fast and effective treatment of wounds, injuries and ulcers contaminated withStaphylococcus aureus andPseudomonas aeruginosa;

  • responses to the increasing antibiotic resistance, which is according to WHO one of the biggest threats to global health;

  • has been successfully developed by the Czech biotech company



  • also known informally as phages, are viruses that infect bacteria and destroy their cells;

  • were discovered already in 1896 and described in 1915 - even before penicillin (1928);

  • are highly selective - they only attack their host bacteria, they are harmless to other microorganisms, people, animals, and plants;

  • are a natural part of the microbial world and are the good guys of the virology world;

  • effectively fight also the most dangerous forms of antibiotic-resistant bacteria.


  • is a Czech company focused on research, development and innovation in the field of microbiology and biotechnology;

  • was established in 2012; in 2016 the company received a GMP certificate to produce bacteriophages as medicinal products;

  • the main research and production activities include the production of bacteria-based products, mainly in three main segments:

i) bacterial lysates,

ii) phage lysates and

iii) bacterial enzymes



Do you identify DUOFAG® as an ideal subject for investment?
MB Pharma opens an opportunity to invest in the DUOFAG® clinical trials.
For further discussions,contact us.

bottom of page